Sunesis Pharmaceuticals (SNSS) - SNS-062 trial up and running

07:19 EDT 3 Aug 2017 | Edison Investment Research

Edison Investment Research - Pharmaceutical & healthcare - Sunesis Pharmaceuticals: Sunesis announced on 18 July 2017 that the first patient had been dosed in its Phase Ib/II study of SNS-062 for the treatment of chronic lymphocytic leukemia (CLL) and other B-cell cancers. The trial is a dose-ranging and expansion study enrolling relapsed and refractory patients, and will enroll up to 124 patients. The company announced on the Q217 conference call that it expects to have identified the correct dose and to provide an update in spring 2018.
ISIN: US8673287004

Original Article: Sunesis Pharmaceuticals (SNSS) - SNS-062 trial up and running


More From BioPortfolio on "Sunesis Pharmaceuticals (SNSS) - SNS-062 trial up and running"

Quick Search

Relevant Topic

Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...